I

n a damning report, a major shareholder advisory firm is recommending that Mylan stockholders vote to remove 10 incumbent board members — including non-executive chairman Robert Coury and chief executive officer Heather Bresch — over the EpiPen pricing scandal and subsequent investigations. The company holds its annual meeting on June 22.

In explaining its recommendations, Institutional Shareholder Services argued the Mylan board is responsible for “significant destruction” in shareholder value and “material failures” over a number of years to respond to “warning signs,” but failed to take action to mitigate or head off the risks. As a result, the company also suffered “long-term reputational damage.”

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X